Cytomegalovirus (CMV), a beta-herpesvirus capable of maintaining lifelong latency, presents a substantial risk to transplant recipients, resulting in significant morbidity and mortality among both ...

Acyclovir 400–800 mg p.o. b.i.d. Valacyclovir 500 mg p.o. b.i.d. Famciclovir 500 mg p.o. b.i.d. Acyclovir 400 mg p.o. t.i.d. Valacyclovir 1 g p.o. b.i.d ...

More than 55% of transplant recipients with refractory CMV infections achieved confirmed viral clearance with Takeda's drug, compared to around 24% of those on conventional antivirals.

in immunocompromised patients such as transplant recipients, reactivation of latent virus can result in severe disease. Patient monitoring, including quantitative nucleic acid testing (QNAT), may play ...